DCPH - Deciphera Pharmaceuticals, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 14.65

Open

$ 14.31

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 14.28 - $ 14.83

52 Week Range

$ 9.90 - $ 17.73

Volume

330,362

Average Volume

Market Cap

1.25B

Beta (5Y Monthly)

$ 0.79

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-07-2024	12-31-2023	10-K
2	10-30-2023	09-30-2023	10-Q
3	08-09-2023	06-30-2023	10-Q
4	05-03-2023	03-31-2023	10-Q
5	02-07-2023	12-31-2022	10-K
6	11-03-2022	09-30-2022	10-Q
7	08-04-2022	06-30-2022	10-Q
8	05-04-2022	03-31-2022	10-Q
9	02-08-2022	12-31-2021	10-K
10	11-02-2021	09-30-2021	10-Q
11	08-03-2021	06-30-2021	10-Q
12	05-04-2021	03-31-2021	10-Q
13	02-09-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-04-2020	06-30-2020	10-Q
16	05-05-2020	03-31-2020	10-Q
17	03-09-2020	12-31-2019	10-K
18	11-04-2019	09-30-2019	10-Q
19	08-02-2019	06-30-2019	10-Q
20	05-09-2019	03-31-2019	10-Q
21	03-14-2019	12-31-2018	10-K
22	11-08-2018	09-30-2018	10-Q
23	08-07-2018	06-30-2018	10-Q
24	05-08-2018	03-31-2018	10-Q
25	03-28-2018	12-31-2017	10-K
26	11-14-2017	09-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Deciphera Pharmaceuticals' Cash Position A...
02/06/2024 12:03:05

Deciphera Pharmaceuticals Q4 EPS $(0.54) B...
02/06/2024 12:01:33

Deciphera Pharmaceuticals (NASDAQ:DCPH) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimat...

Earnings Scheduled For February 6, 2024
02/06/2024 10:42:06

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of ...

Earnings Outlook For Deciphera Pharmaceuti...
02/05/2024 19:02:18

Deciphera Pharmaceuticals Results Of INTRI...
01/18/2024 16:17:52

Results of INTRIGUE Study Long-Term Follow-UpIn INTRIGUE, 453 patients in the all-patient intent-to-treat population (AP-ITT) w...

Deciphera Pharmaceuticals Presents Long-Te...
01/18/2024 16:14:46

– Median Overall Survival for QINLOCK® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Popul...

Genesis Pharma And Deciphera Pharmaceutica...
01/12/2024 11:39:41

Deciphera Pharmaceuticals Preliminary Unau...
01/08/2024 12:17:51

Deciphera Pharmaceuticals' Preliminary Una...
01/08/2024 12:17:08

Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Applicatio...

Deciphera Pharmaceuticals Announces Nature...
01/05/2024 12:02:10

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializ...

What 4 Analyst Ratings Have To Say About D...
11/20/2023 19:00:35

JP Morgan Reinstates Neutral on Deciphera ...
11/20/2023 13:17:17

JP Morgan analyst Jessica Fye reinstates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Neutral and announces $14 price target.

Stifel Maintains Buy on Deciphera Pharmace...
10/31/2023 18:00:34

Stifel analyst Bradley Canino maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the price target from ...

HC Wainwright & Co. Maintains Buy on Decip...
10/31/2023 11:36:49

HC Wainwright & Co. analyst Andrew Fein maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the pric...

JonesTrading Upgrades Deciphera Pharmaceut...
10/31/2023 09:52:03

JonesTrading analyst Soumit Roy upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy.

Piper Sandler Upgrades Deciphera Pharmaceu...
10/30/2023 16:58:26

Piper Sandler analyst Christopher Raymond upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight and ra...

deciphera-pharmaceuticals-investigational-drug-shows-encouraging-response-rates-in-rare-type-of-cancer

Deciphera Pharmaceuticals' Investigational...
10/30/2023 15:22:10

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patient...

Western Digital, JinkoSolar, Lumentum Hold...
10/30/2023 14:19:29

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording...

Market-Moving News for October 30th
10/30/2023 12:50:10

DCPH: 38% | Deciphera Pharma shares are trading higher after the company announced its study of patients with TGCT met its prim...

Deciphera Pharmaceuticals Shares Resumed a...
10/30/2023 11:34:23